跳至內容

羅索那班

維基百科,自由的百科全書
羅索那班
臨床資料
ATC碼
  • 未分配
識別資訊
  • (±)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(1-piperidinyl)-4,5-dihydro-1H-pyrazole-3-carboxamide
CAS號861151-12-4
PubChem CID
ChemSpider
UNII
CompTox Dashboard英語CompTox Chemicals Dashboard (EPA)
化學資訊
化學式C21H21Cl3N4O
摩爾質量451.78 g·mol−1
3D模型(JSmol英語JSmol
  • O=C(NN1CCCCC1)\C4=N\N(c2ccc(Cl)cc2Cl)C(c3ccc(Cl)cc3)C4
  • InChI=1S/C21H21Cl3N4O/c22-15-6-4-14(5-7-15)20-13-18(21(29)26-27-10-2-1-3-11-27)25-28(20)19-9-8-16(23)12-17(19)24/h4-9,12,20H,1-3,10-11,13H2,(H,26,29)
  • Key:WMMMJGKFKKBRQR-UHFFFAOYSA-N

羅索那班INN:Rosonabant,開發代號:E-6776)或譯作羅索納班,是一種用作CB1受體拮抗劑/反向激動劑藥物埃斯特夫正在研究將其作為治療肥胖症食慾抑制劑[1][2]在相關的CB1拮抗劑利莫那班於2008年11月停用後不久,臨床用藥的開發明顯停止,原因是有報道稱其及其它類似藥劑會引起嚴重的精神不良反應,例如焦慮抑鬱自殺意念[3][4][5]

參見

[編輯]

參考資料

[編輯]
  1. ^ Janero DR, Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opinion on Emerging Drugs. March 2009, 14 (1): 43–65. PMID 19249987. S2CID 74250986. doi:10.1517/14728210902736568. 
  2. ^ Tim C. Kirkham; S. J. Cooper. Appetite and Body Weight: Integrative Systems and the Development of Anti-Obesity Drugs. Academic Press. 2007: 325 [12 May 2012]. ISBN 978-0-12-370633-1. 
  3. ^ Heal DJ, Gosden J, Smith SL. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. British Journal of Clinical Pharmacology. December 2009, 68 (6): 861–74. PMC 2810797可免費查閱. PMID 20002080. doi:10.1111/j.1365-2125.2009.03549.x. 
  4. ^ Lee HK, Choi EB, Pak CS. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Current Topics in Medicinal Chemistry. 2009, 9 (6): 482–503. PMID 19689362. doi:10.2174/156802609788897844. (原始內容存檔於2013-05-22). 
  5. ^ Moreira, Fabrício A.; Crippa, José Alexandre S. The psychiatric side-effects of rimonabant. Revista Brasileira de Psiquiatria. June 2009, 31 (2): 145–153. ISSN 1516-4446. PMID 19578688. doi:10.1590/S1516-44462009000200012可免費查閱.